Talk Details · IDC 2027

Efficacy of 2% tofacitinib ointment versus 0.1% tacrolimus ointment in patients of vitiligo: A hospital-based, double-blinded, randomised controlled trial

Oral · In-Person · Day 1

Abstract

About this talk

Introduction: The interferon-γ/JAK-STAT/CXCL10 signaling axis plays a central role in melanocyte destruction in vitiligo, providing a mechanistic rationale for targeted Janus kinase (JAK) inhibition. Although topical JAK inhibitors represent an emerging therapeutic strategy, robust comparative evidence for topical tofacitinib against established immunomodulators remains limited.

Objective: To compare the efficacy and safety of topical 2% tofacitinib and 0.1% tacrolimus in non-mucosal vitiligo, with emphasis on lesion-level repigmentation, patient-reported outcomes, and anatomical variations in treatment response.

Materials and Methods: This hospital-based, double-blind, parallel-group randomized controlled trial enrolled 85 adults with 121 non-mucosal vitiligo lesions involving less than 5% body surface area. The calculated sample size was 42 lesions per arm. Participants were randomized to topical 2% tofacitinib or 0.1% tacrolimus, with both arms receiving a standardized tapering course of mometasone furoate 0.1% during the initial eight weeks. Clinical and dermoscopic assessments were performed every four weeks over 24 weeks. Treatment success was defined as a Vitiligo Noticeability Scale (VNS) score ≥4 with >50% repigmentation, while good response required VNS ≥4 with >75% repigmentation. Efficacy was evaluated at both lesion and patient levels, with additional analyses by anatomical site and vitiligo subtype.

Results: Eighty-five patients (121 lesions) were randomised, 42 to tacrolimus and 43 to tofacitinib, and 60 patients (88 lesions) completed 24 weeks. The arms were comparable at baseline. Lesion-level treatment success was 66.7% with tofacitinib versus 39.5% with tacrolimus (p = 0.018), and good response (more than 75% repigmentation) was 53.3% versus 27.9% (p = 0.018). Patient-level success was 75.0% versus 53.6% (p = 0.11). Both treatments produced significant improvement from baseline (p<0.001). The median time to first repigmentation response was 8 weeks with tofacitinib and 12 weeks with tacrolimus (p = 0.002). The advantage of tofacitinib was greatest in non-segmental vitiligo (68.8% versus 32.3%) and at non-acral sites (67.5% versus 39.4%, p = 0.020). On dermoscopy, marginal and perifollicular repigmentation were the predominant patterns and appeared at a median of 4 weeks in both arms. Leukotrichia did not repigment in either arm. Adverse effects were mild and transient, with no serious adverse event.

Discussion/Conclusion: In a double-blind randomized controlled, topical 2% tofacitinib produced greater and faster repigmentation than topical 0.1% tacrolimus over 24 weeks, with comparable tolerability. These findings support the potential of topical tofacitinib as a targeted therapeutic option for localized vitiligo. While topical ruxolitinib 1.5% cream is FDA-approved for non-segmental vitiligo in patients aged 12 years and older, topical tofacitinib remains non-FDA-approved for this indication. Our findings highlight its potential as an alternative topical JAK inhibitor, particularly in settings where access to approved therapies is limited. Larger, adequately powered trials with longer follow-up are however needed to confirm efficacy, safety, and durability of repigmentation.

Keywords: Vitiligo, Tofacitinib, tacrolimus, Janus kinase inhibitor, Randomised controlled trial.

Speaker

About the speaker

Kavita Swami

Kavita Swami

All India Institute of Medical Sciences, Gorakhpur, India

View full speaker profile →

Join the IDC 2027 delegation

Rome · June 21–23, 2027 · Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.